1
|
Yang W, Gong Y, Wang Y, Wu C, Zhang X, Li J, Wu D. Design of gum Arabic/gelatin composite microcapsules and their cosmetic applications in encapsulating tea tree essential oil. RSC Adv 2024; 14:4880-4889. [PMID: 38323015 PMCID: PMC10845123 DOI: 10.1039/d3ra08526k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 01/18/2024] [Indexed: 02/08/2024] Open
Abstract
Microencapsulation has been widely used to protect essential oils, facilitating their application in cosmetics. In this study, gelatin, gum arabic and n-butyl cyanoacrylate were used as wall materials, and composite microcapsules of tea tree essential oil (TTO) were prepared using a combination of composite coagulation and in situ polymerization methods. When the ratio of gelatin to gum arabic is 1 : 1, the ratio of TTO to n-butyl cyanoacrylate is 4 : 1, the curing time is 10 h, and the encapsulation efficiency (EE) under these conditions is 73.61%. Morphological observation showed that the composite capsule was a micron-sized spherical particle with an average particle size of 10.51 μm, and Fourier transform infrared spectroscopy (FT-IR) confirmed a complex coagulation reaction between gelatin and gum arabic, and the disappearance of the n-butyl cyanoacrylate peak indicated that the film was formed in a condensation layer. The thermogravimetric analysis (TGA) results showed that the composite capsule greatly improved the thermal stability of TTO. Rheological testing showed that the viscosity and viscoelasticity of the surface composite capsules have been improved. In addition, the composite capsule showed good stability in the osmotic environment and has good sustained-release performance and antioxidant capacity in the average human skin environment.
Collapse
Affiliation(s)
- Wei Yang
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
- Heilongjiang Provincial Key Laboratory of New Drug Development and Pharmacotoxicological Evaluation, Jiamusi University Jiamusi 154007 P. R. China
| | - Yuxi Gong
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
| | - Yansong Wang
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
| | - Chao Wu
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
| | - Xiangyu Zhang
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
- Heilongjiang Provincial Key Laboratory of New Drug Development and Pharmacotoxicological Evaluation, Jiamusi University Jiamusi 154007 P. R. China
| | - Jinlian Li
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
- Heilongjiang Provincial Key Laboratory of New Drug Development and Pharmacotoxicological Evaluation, Jiamusi University Jiamusi 154007 P. R. China
| | - Dongmei Wu
- College of Pharmacy, Jiamusi University Jiamusi Heilongjiang 154007 P. R. China
- Heilongjiang Provincial Key Laboratory of New Drug Development and Pharmacotoxicological Evaluation, Jiamusi University Jiamusi 154007 P. R. China
| |
Collapse
|
2
|
Spoorthi Shetty S, Halagali P, Johnson AP, Spandana KMA, Gangadharappa HV. Oral insulin delivery: Barriers, strategies, and formulation approaches: A comprehensive review. Int J Biol Macromol 2023:125114. [PMID: 37263330 DOI: 10.1016/j.ijbiomac.2023.125114] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 05/23/2023] [Accepted: 05/24/2023] [Indexed: 06/03/2023]
Abstract
Diabetes Mellitus is characterized by a hyperglycemic condition which can either be caused by the destruction of the beta cells or by the resistance developed against insulin in the cells. Insulin is a peptide hormone that regulates the metabolism of carbohydrates, proteins, and fats. Type 1 Diabetes Mellitus needs the use of Insulin for efficient management. However invasive methods of administration may lead to reduced adherence by the patients. Hence there is a need for a non-invasive method of administration. Oral Insulin has several merits over the conventional method including patient compliance, and reduced cost, and it also mimics endogenous insulin and hence reaches the liver by the portal vein at a higher concentration and thereby showing improved efficiency. However oral Insulin must pass through several barriers in the gastrointestinal tract. Some strategies that could be utilized to bypass these barriers include the use of permeation enhancers, absorption enhancers, use of suitable polymers, use of suitable carriers, and other agents. Several formulation types have been explored for the oral delivery of Insulin like hydrogels, capsules, tablets, and patches which have been described briefly by the article. A lot of attempts have been made for developing oral insulin delivery however none of them have been commercialized due to numerous shortcomings. Currently, there are several formulations from the companies that are still in the clinical phase, the success or failure of some is yet to be seen in the future.
Collapse
Affiliation(s)
- S Spoorthi Shetty
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
| | - Praveen Halagali
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
| | - Asha P Johnson
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
| | - K M Asha Spandana
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
| | - H V Gangadharappa
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India.
| |
Collapse
|
3
|
Zhang T, Tang JZ, Fei X, Li Y, Song Y, Qian Z, Peng Q. Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery? Acta Pharm Sin B 2021; 11:651-667. [PMID: 33777673 PMCID: PMC7982494 DOI: 10.1016/j.apsb.2020.08.016] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 07/09/2020] [Accepted: 08/03/2020] [Indexed: 02/05/2023] Open
Abstract
Insulin therapy plays an essential role in the treatment of diabetes mellitus. However, frequent injections required to effectively control the glycemic levels lead to substantial inconvenience and low patient compliance. In order to improve insulin delivery, many efforts have been made, such as developing the nanoparticles (NPs)-based release systems and oral insulin. Although some improvements have been achieved, the ultimate results are still unsatisfying and none of insulin-loaded NPs systems have been approved for clinical use so far. Recently, nano‒protein interactions and protein corona formation have drawn much attention due to their negative influence on the in vivo fate of NPs systems. As the other side of a coin, such interactions can also be used for constructing advanced drug delivery systems. Herein, we aim to provide an insight into the advance and flaws of various NPs-based insulin delivery systems. Particularly, an interesting discussion on nano‒protein interactions and its potentials for developing novel insulin delivery systems is initiated. Insulin therapy plays essential roles in treating diabetes. Optimizing insulin delivery enhances insulin therapy. Nanoparticles are promising systems for delivery of insulin. Nano-protein interactions influence the delivery of nanoparticles. Nano-protein interactions can be used for advanced delivery of insulin.
Collapse
Affiliation(s)
- Ting Zhang
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
| | - James Zhenggui Tang
- Research Institute in Healthcare Science, Faculty of Science and Engineering, School of Pharmacy, University of Wolverhampton, Wolverhampton, WV1 1LY, UK
| | - Xiaofan Fei
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Yanping Li
- Laboratory of Clinical Pharmacy and Adverse Drug Reaction, West China Hospital of Sichuan University, Chengdu 610041, China
| | - Yi Song
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Zhiyong Qian
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China
| | - Qiang Peng
- State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
- Corresponding author.
| |
Collapse
|
4
|
Wong CY, Al-Salami H, Dass CR. Cellular assays and applied technologies for characterisation of orally administered protein nanoparticles: a systematic review. J Drug Target 2020; 28:585-599. [DOI: 10.1080/1061186x.2020.1726356] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Chun Y. Wong
- School of Pharmacy and Biomedical Science, Curtin University, Bentley, Australia
- Curtin Health Innovation Research Institute, Bentley, Australia
| | - Hani. Al-Salami
- School of Pharmacy and Biomedical Science, Curtin University, Bentley, Australia
- Curtin Health Innovation Research Institute, Bentley, Australia
- Biotechnology and Drug Development Research Laboratory, Curtin University, Bentley, Australia
| | - Crispin R. Dass
- School of Pharmacy and Biomedical Science, Curtin University, Bentley, Australia
- Curtin Health Innovation Research Institute, Bentley, Australia
| |
Collapse
|
5
|
Vauthier C. A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles. J Drug Target 2019; 27:502-524. [PMID: 30889991 DOI: 10.1080/1061186x.2019.1588280] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Starting in the late 1970s, the pioneering work of Patrick Couvreur gave birth to the first biodegradable nanoparticles composed of a biodegradable synthetic polymer. These nanoparticles, made of poly(alkylcyanoacrylate) (PACA), were the first synthetic polymer-based nanoparticulate drug carriers undergoing a phase III clinical trial so far. Analyzing the journey from the birth of PACA nanoparticles to their clinical evaluation, this paper highlights their remarkable adaptability to bypass various drug delivery challenges found on the way. At present, PACA nanoparticles include a wide range of nanoparticles that can associate drugs of different chemical nature and can be administered in vivo by different routes. The most recent technologies giving the nanoparticles customised functions could also be implemented on this family of nanoparticles. Through different examples, this paper discusses the seminal role of the PACA nanoparticles' family in the development of nanomedicines.
Collapse
Affiliation(s)
- Christine Vauthier
- a Institut Galien Paris Sud, UMR CNRS 8612 , Université Paris-Sud , Chatenay-Malabry Cedex , France
| |
Collapse
|
6
|
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2019; 95:19-28. [DOI: 10.1016/j.msec.2018.10.064] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 09/09/2018] [Accepted: 10/17/2018] [Indexed: 02/06/2023]
|
7
|
Siwach R, Pandey P, Chawla V, Dureja H. Role of Nanotechnology in Diabetic Management. RECENT PATENTS ON NANOTECHNOLOGY 2019; 13:28-37. [PMID: 30608045 DOI: 10.2174/1872210513666190104122032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 11/12/2018] [Accepted: 12/10/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people worldwide in the last few decades. Nanotechnology is a discipline that is concerned with material characteristics at nanoscale and offers novel techniques for disease detection, management and prevention. OBJECTIVE Diabetes mellitus is an epidemic disease that has affected millions of people globally. Nanotechnology has greatly enhanced the health status by providing non-obtrusive techniques for the management and treatment of diabetic patients. METHOD In diabetes research, the nanotechnology has encouraged the advancement of novel glucose monitoring and several modalities for insulin delivery holding possibilities to enhance the personal satisfaction and life quality for diabetic patients. RESULT Nanoparticles hold a great potential in the areas of drug delivery and are explored as vehicles for orally administered insulin formulations. Glucose biosensors equipped with nanoscale materials such as Quantum Dots (QDs), Carbon Nanotubes (CNTs), Magnetic Nanoparticles (MNPs) etc. have shown greater sensitivity. Nanotechnology in diabetic research is heading towards the novel techniques which can provide continuous glucose monitoring offering accurate information and improving patient's compliance. CONCLUSION The present review addresses the different aspects of nanoparticles and recent patents related to diabetic management based on nanotechnology.
Collapse
Affiliation(s)
- Reena Siwach
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak-124001, India
| | - Parijat Pandey
- Shri Baba Mastnath Institute of Pharmaceutical Sciences and Research, Baba Mastnath University, Rohtak-124001, India
| | - Viney Chawla
- Department of Pharmaceutics, University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot-151203, India
| | - Harish Dureja
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak-124001, India
| |
Collapse
|
8
|
P.V. J, Nair SV, Kamalasanan K. Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes. Colloids Surf B Biointerfaces 2017; 153:123-131. [DOI: 10.1016/j.colsurfb.2017.02.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 02/01/2017] [Accepted: 02/13/2017] [Indexed: 02/07/2023]
|
9
|
Lakkireddy HR, Urmann M, Besenius M, Werner U, Haack T, Brun P, Alié J, Illel B, Hortala L, Vogel R, Bazile D. Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev 2016; 106:196-222. [PMID: 26964477 DOI: 10.1016/j.addr.2016.02.011] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Revised: 02/23/2016] [Accepted: 02/28/2016] [Indexed: 12/12/2022]
Abstract
While some orally delivered diabetes peptides are moving to late development with standard formulations incorporating functional excipients, the demonstration of the value of nanotechnology in clinic is still at an early stage. The goal of this review is to compare these two drug delivery approaches from a physico-chemical and a biopharmaceutical standpoint in an attempt to define how nanotechnology-based products can be differentiated from standard oral dosage forms for oral bioavailability of diabetes peptides. Points to consider in a translational approach are outlined to seize the opportunities offered by a better understanding of both the intestinal barrier and of nano-carriers designed for oral delivery.
Collapse
Affiliation(s)
- Harivardhan Reddy Lakkireddy
- Drug Delivery Technologies and Innovation, Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Vitry-sur-Seine, France
| | - Matthias Urmann
- Diabetes Division, Sanofi Research and Development, Frankfurt, Germany
| | - Melissa Besenius
- Diabetes Division, Sanofi Research and Development, Frankfurt, Germany
| | - Ulrich Werner
- Diabetes Division, Sanofi Research and Development, Frankfurt, Germany
| | - Torsten Haack
- Diabetes Division, Sanofi Research and Development, Frankfurt, Germany
| | - Priscilla Brun
- Disposition Safety and Animal Research, Sanofi Research and Development, Montpellier, France
| | - Jean Alié
- Analytical Sciences, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France
| | - Brigitte Illel
- Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France
| | - Laurent Hortala
- Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France
| | - Rachel Vogel
- Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France
| | - Didier Bazile
- Drug Delivery Technologies and Innovation, Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Vitry-sur-Seine, France.
| |
Collapse
|
10
|
Nanoparticle delivery and particle diffusion in confined and complex environments. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.06.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
11
|
Fonte P, Araújo F, Silva C, Pereira C, Reis S, Santos HA, Sarmento B. Polymer-based nanoparticles for oral insulin delivery: Revisited approaches. Biotechnol Adv 2015; 33:1342-54. [PMID: 25728065 DOI: 10.1016/j.biotechadv.2015.02.010] [Citation(s) in RCA: 145] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 12/29/2014] [Accepted: 02/18/2015] [Indexed: 10/23/2022]
Abstract
Diabetes mellitus is a high prevalence and one of the most severe and lethal diseases in the world. Insulin is commonly used to treat diabetes in order to give patients a better life condition. However, due to bioavailability problems, the most common route of insulin administration is the subcutaneous route, which may present patients compliance problems to treatment. The oral administration is thus considered the most convenient alternative to deliver insulin, but it faces important challenges. The low stability of insulin in the gastrointestinal tract and low intestinal permeation, are problems to overcome. Therefore, the encapsulation of insulin into polymer-based nanoparticles is presented as a good strategy to improve insulin oral bioavailability. In the last years, different strategies and polymers have been used to encapsulate insulin and deliver it orally. Polymers with distinct properties from natural or synthetic sources have been used to achieve this aim, and among them may be found chitosan, dextran, alginate, poly(γ-glutamic acid), hyaluronic acid, poly(lactic acid), poly(lactide-co-glycolic acid), polycaprolactone (PCL), acrylic polymers and polyallylamine. Promising studies have been developed and positive results were obtained, but there is not a polymeric-based nanoparticle system to deliver insulin orally available in the market yet. There is also a lack of long term toxicity studies about the safety of the developed carriers. Thus, the aims of this review are first to provide a deep understanding on the oral delivery of insulin and the possible routes for its uptake, and then to overview the evolution of this field in the last years of research of insulin-loaded polymer-based nanoparticles in the academic and industrial fields. Toxicity concerns of the discussed nanocarriers are also addressed.
Collapse
Affiliation(s)
- Pedro Fonte
- REQUINTE, Department of Chemical Sciences-Applied Chemistry Lab, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal
| | - Francisca Araújo
- CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal; ICBAS-Instituto Ciências Biomédicas Abel Salazar, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal; INEB-Instituto de Engenharia Biomédica, University of Porto, Rua do Campo Alegre 823, 4150-180 Porto, Portugal; Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland
| | - Cátia Silva
- CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal
| | - Carla Pereira
- INEB-Instituto de Engenharia Biomédica, University of Porto, Rua do Campo Alegre 823, 4150-180 Porto, Portugal
| | - Salette Reis
- REQUINTE, Department of Chemical Sciences-Applied Chemistry Lab, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
| | - Hélder A Santos
- Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland
| | - Bruno Sarmento
- CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116 Gandra PRD, Portugal; INEB-Instituto de Engenharia Biomédica, University of Porto, Rua do Campo Alegre 823, 4150-180 Porto, Portugal.
| |
Collapse
|
12
|
Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug Deliv 2014; 23:2371-2390. [PMID: 25544604 DOI: 10.3109/10717544.2014.991001] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
CONTEXT Existing medication systems for the treatment of diabetes mellitus (DM) are inconvenient and troublesome for effective and safe delivery of drugs to the specific site. Therefore, investigations are desired to deliver antidiabetics using novel delivery approaches followed by their commercialization. OBJECTIVE The present review aims to provide a compilation on the latest development in the field of novel drug delivery systems (NDDSs) for antidiabetics with special emphasis on particulate, vesicular and miscellaneous systems. METHODS Review of literature (restricted to English language only) was done using electronic databases like Pubmed® and Scirus, i.e. published during 2005-2013. The CIMS/MIMS India Medical Drug Information eBook was used regarding available marketed formulation of antidiabetic drugs. Keywords used were "nanoparticle", "microparticle", "liposomes", "niosomes", "transdermal systems", "insulin", "antidiabetic drugs" and "novel drug delivery systems". Single inclusion was made for one article. If in vivo study was not done then article was seldom included in the manuscript. RESULTS The curiosity to develop NDDSs of antidiabetic drugs with special attention to the nanoparticulate system followed by microparticulate and lipid-based system is found to emerge gradually to overcome the problems associated with the conventional dosage forms and to win the confidence of end users towards the higher acceptability. CONCLUSION In the current scientific panorama when the area of novel drug delivery system has been recognized for its palpable benefits, unique potential of providing physical stability, sustained and site-specific drug delivery for a scheduled period of time can open new vistas for precise, safe and quality treatment of DM.
Collapse
Affiliation(s)
- Vineet Kumar Rai
- a Herbal Medicinal Products Department , CSIR - Central Institute of Medicinal and Aromatic Plants , Lucknow , Uttar Pradesh , India and
| | - Nidhi Mishra
- a Herbal Medicinal Products Department , CSIR - Central Institute of Medicinal and Aromatic Plants , Lucknow , Uttar Pradesh , India and
| | - Ashish Kumar Agrawal
- b Department of Pharmaceutics , National Institute of Pharmaceutical Education and Research , Mohali , Punjab , India
| | - Sanyog Jain
- b Department of Pharmaceutics , National Institute of Pharmaceutical Education and Research , Mohali , Punjab , India
| | - Narayan Prasad Yadav
- a Herbal Medicinal Products Department , CSIR - Central Institute of Medicinal and Aromatic Plants , Lucknow , Uttar Pradesh , India and
| |
Collapse
|
13
|
Ramesan RM, Sharma CP. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev Med Devices 2014; 6:665-76. [DOI: 10.1586/erd.09.43] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
14
|
Sánchez-Leija RJ, Pojman JA, Luna-Bárcenas G, Mota-Morales JD. Controlled release of lidocaine hydrochloride from polymerized drug-based deep-eutectic solvents. J Mater Chem B 2014; 2:7495-7501. [DOI: 10.1039/c4tb01407c] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
This work takes advantage of the transformation of lidocaine hydrochloride into deep-eutectic solvents (DESs) – ionic liquid analogues – to incorporate polymerizable counterparts into DESs, such that polymer–drug complexes are synthesized by free-radical frontal polymerization without the use of a solvent.
Collapse
Affiliation(s)
- R. J. Sánchez-Leija
- Polymer & Biopolymer Research Group
- Centro de Investigación y de Estudios Avanzados
- Querétaro, Mexico
| | - J. A. Pojman
- Department of Chemistry
- Louisiana State University
- Baton Rouge, USA
| | - G. Luna-Bárcenas
- Polymer & Biopolymer Research Group
- Centro de Investigación y de Estudios Avanzados
- Querétaro, Mexico
| | | |
Collapse
|
15
|
Park MJ, Balakrishnan P, Yang SG. Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. Int J Pharm 2012; 441:757-64. [PMID: 23089581 DOI: 10.1016/j.ijpharm.2012.10.018] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2012] [Revised: 09/19/2012] [Accepted: 10/11/2012] [Indexed: 11/29/2022]
Abstract
Self-microemulsifying drug delivery system (SEDDS) cored-polymeric nanocapsules (NC) were fabricated using emulsion diffusion method for the controlled oral absorption of the poorly water soluble drug, cyclosporine. Poly-dl-lactide (PDLLA) was used as the shell-forming polymer. The NCs in different polymer/oil ratios (from 25/125 to 125/125) were prepared following a solvent-diffusion method. Especially, the SEDDS oil-core compositions, which can form microemulsions on dispersion, were selected based on a pseudo-phase diagram study and further optimized based on the solubility and permeability studies. The prepared NCs were with a mean diameter of 150-220 nm and 9.4-4.5% w/w drug loading. In vivo study in rats showed that the optimized NC(50/125) and NC(100/125) released the drug in controlled way as well as enhanced the bioavailability significantly with AUC(0-24h) values of 14880.3±1470.6 and 12657.8±754.5 ng h/ml, respectively, compared to that of SEDDS-core solution (9878.9±409.6 ng h/ml). Moreover it was observed that the NCs maintained blood concentration of cyclosporine (>500 ng/ml) for 14-20 h but in the case of control formulation it was only 7.33 h. Our results suggest that the prepared NCs could be a potential carrier for the oral controlled release formulation of cyclosporine.
Collapse
Affiliation(s)
- Min-Jeong Park
- Department of Drug Development and UNIDDS, School of Medicine, Inha University, 8F A-dong, Jeongseok Bldg., Sinheung-dong 3-ga, Jung-gu, Incheon 400-712, South Korea
| | | | | |
Collapse
|
16
|
Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012; 161:781-94. [PMID: 22659331 DOI: 10.1016/j.jconrel.2012.05.040] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2012] [Revised: 05/21/2012] [Accepted: 05/22/2012] [Indexed: 01/20/2023]
Abstract
This review highlights the recent developments in the area of nanocarrier-based mucosal delivery of therapeutic biomolecules and antigens. Macromolecular drugs have the unique power to tackle challenging diseases but their structure, physicochemical properties, stability, pharmacodynamics, and pharmacokinetics place stringent demands on the way they are delivered into the body (e.g., inability to cross mucosal surfaces and biological membranes). Carrier-based drug delivery systems can diminish the toxicity of therapeutic biomolecules, improve their bioavailability and make possible their administration via less-invasive routes (e.g., oral, nasal, pulmonary, etc.). Thus, the development of functionalized nanocarriers and nanoparticle-based microcarriers for the delivery of macromolecular drugs is considered an important scientific challenge and at the same time a business breakthrough for the biopharmaceutical industry. In order to be translated to the clinic the nanocarriers need to be biocompatible, biodegradable, stable in biological media, non-toxic and non-immunogenic, to exhibit mucoadhesive properties, to cross mucosal barriers and to protect their sensitive payload and deliver it to its target site in a controlled manner, thus increasing significantly its bioavailability and efficacy.
Collapse
Affiliation(s)
- Olga Kammona
- Chemical Process Engineering Research Institute, Centre for Research and Technology Hellas, P.O. Box 60361, 57001 Thessaloniki, Greece
| | | |
Collapse
|
17
|
Abstract
Oral peptide delivery has been one of the major challenges of pharmaceutical sciences as it could lead to a great improvement of classical therapies, such as insulin, alongside making an important number of new therapies feasible. Successful oral delivery needs to fulfill two key tasks: to protect the macromolecules from degradation in the GI tract and to shuttle them across the intestinal epithelium in a safe and efficient fashion. Over the last decade, there have been numerous approaches based on the chemical modification of peptides and on the use of permeation enhancers, enzyme inhibitors and drug-delivery systems. Among the approaches developed to overcome these restrictions, the design of nanocarriers seems to be a particularly promising approach. This article is an overview on the state of the art of oral-peptide formulation strategies, with special attention to insulin delivery and the use of polymeric nanocarriers as delivery systems.
Collapse
|
18
|
Abstract
Since its discovery, insulin has been used as highly specific and effective therapeutic protein to treat type 1 diabetes and later was associated to oral antidiabetic agents in the treatment of type 2 diabetes. Generally, insulin is administered parenterally. Although this route is successful, it still has several limitations, such as discomfort, pain, lipodystrophy at the injection sites and peripheral hyperinsulinemia, which may be the cause of side effects and some complications. Thus, alternative routes of administration have been developed, namely, those based on nanotechnologies. Nanoparticles, made of synthetic or natural materials, have been shown to successfully overcome the inherent barriers for insulin stability, degradation, and uptake across the gastrointestinal tract and other mucosal membranes. This review describes some of the many attempts made to develop alternative and more convenient routes for insulin delivery.
Collapse
|
19
|
Card JW, Magnuson BA. A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems. Am J Physiol Gastrointest Liver Physiol 2011; 301:G956-67. [PMID: 21921287 DOI: 10.1152/ajpgi.00107.2011] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Nanotechnology is providing new and innovative means to detect, diagnose, and treat disease. In this regard, numerous nanoparticle-based approaches have been taken in an effort to develop an effective oral insulin therapy for the treatment of diabetes. This review summarizes efficacy data from studies that have evaluated oral insulin therapies in experimental models. Also provided here is an overview of the limited safety data that have been reported in these studies. To date, the most promising approaches for nanoparticle-based oral insulin therapy appear to involve the incorporation of insulin into complex multilayered nanoparticles that are mucoadhesive, biodegradable, biocompatible, and acid protected and into nanoparticles that are designed to take advantage of the vitamin B(12) uptake pathway. It is anticipated that the continued investigation and optimization of nanoparticle-based formulations for oral delivery of insulin will lead to a much sought-after noninvasive treatment for diabetes. Such investigations also may provide insight into the use of nanoparticle-based formulations for peptide- and protein-based oral treatment of other diseases and for various food-related purposes.
Collapse
Affiliation(s)
- Jeffrey W Card
- Cantox Health Sciences International, Intertek Company, Mississauga, Ontario, Canada
| | | |
Collapse
|
20
|
Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials 2011; 33:1583-8. [PMID: 22112760 DOI: 10.1016/j.biomaterials.2011.10.072] [Citation(s) in RCA: 102] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Accepted: 10/27/2011] [Indexed: 02/06/2023]
Abstract
The application of poly(hydroxybutyrate-co-hydroxyhexanoate) (PHBHHx) for sustained and controlled delivery of hydrophilic insulin was made possible by preparing insulin phospholipid complex loaded biodegradable PHBHHx nanoparticles (INS-PLC-NPs). The INS-PLC-NPs produced by a solvent evaporation method showed a spherical shape with a mean particle size, zeta potential and entrapment efficiency of 186.2 nm, -38.4 mv and 89.73%, respectively. In vitro studies demonstrated that only 20% of insulin was released within 31 days with a burst release of 5.42% in the first 8 h. The hypoglycaemic effect in STZ induced diabetic rats lasted for more than 3 days after the subcutaneous injection of INS-PLC-NPs, which significantly prolonged the therapeutic effect compared with the administration of insulin solution. The pharmacological bioavailability (PA) of INS-PLC-NPs relative to insulin solution was over 350%, indicating that the bioavailability of insulin was significantly enhanced by INS-PLC-NPs. Therefore, the INS-PLC-NPs system is promising to serve as a long lasting insulin release formulation, by which the patient compliance can be enhanced significantly. This study also showed that phospholipid complex loaded biodegradable nanoparticles (PLC-NPs) have a great potential to be used as a sustained delivery system for hydrophilic proteins to be encapsulated in hydrophobic polymers.
Collapse
Affiliation(s)
- Qiang Peng
- Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, PR China
| | | | | | | | | |
Collapse
|
21
|
Frost R, Coué G, Engbersen JF, Zäch M, Kasemo B, Svedhem S. Bioreducible insulin-loaded nanoparticles and their interaction with model lipid membranes. J Colloid Interface Sci 2011; 362:575-83. [DOI: 10.1016/j.jcis.2011.05.082] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2011] [Revised: 05/31/2011] [Accepted: 05/31/2011] [Indexed: 12/28/2022]
|
22
|
Mazzaferro S, Bouchemal K, Vauthier C, Gueutin C, Palmieri GF, Ponchel G. What are parameters affecting Leu-enkephalin loading and release from poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan? J Drug Deliv Sci Technol 2011. [DOI: 10.1016/s1773-2247(11)50063-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
Ngwuluka N. Application of in situ polymerization for design and development of oral drug delivery systems. AAPS PharmSciTech 2010; 11:1603-11. [PMID: 21063816 DOI: 10.1208/s12249-010-9535-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Accepted: 10/22/2010] [Indexed: 11/30/2022] Open
Abstract
Although preformed polymers are commercially available for use in the design and development of drug delivery systems, in situ polymerization has also been employed. In situ polymerization affords the platform to tailor and optimize the drug delivery properties of polymers. This review brings to light the benefits of in situ polymerization for oral drug delivery and the possibilities it provides to overcome the challenges of oral route of administration.
Collapse
|
24
|
Graf A, McDowell A, Rades T. Poly(alkycyanoacrylate) nanoparticles for enhanced delivery of therapeutics – is there real potential? Expert Opin Drug Deliv 2009; 6:371-87. [DOI: 10.1517/17425240902870413] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
25
|
Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. Polyelectrolyte Biomaterial Interactions Provide Nanoparticulate Carrier for Oral Insulin Delivery. Drug Deliv 2008; 15:127-39. [DOI: 10.1080/10717540801905165] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
26
|
Chiellini F, Piras AM, Errico C, Chiellini E. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomedicine (Lond) 2008; 3:367-93. [DOI: 10.2217/17435889.3.3.367] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
This review provides an outline of the polymeric micro/nanostructured advanced systems that are suited for the controlled and targeted administration of, specifically, nonconventional drugs. The contribution of new trends in drug-delivery technology is focused on two major parts, dealing with brief surveys of: the biodegradable/bioerodible polymeric systems used in the formulation of micro/nanoparticles and techniques used in the preparation of micro/nanoparticles for their biomedical application in cancer treatment specifically, in inflammation pathologies, as oxygen carriers (blood substitutes) and in tissue-engineering practice. A small discussion of the future perspectives of the described systems is also given.
Collapse
Affiliation(s)
- Federica Chiellini
- Laboratory of Bioactive Polymeric Materials for Biomedical and Environmental Applications - UdR INSTM - Department of Chemistry & Industrial Chemistry, University of Pisa, Via Vecchia Livornese,1291, 56010, S. Piero a Grado (Pisa), Italy
| | - Anna Maria Piras
- Laboratory of Bioactive Polymeric Materials for Biomedical and Environmental Applications - UdR INSTM - Department of Chemistry & Industrial Chemistry, University of Pisa, Via Vecchia Livornese,1291, 56010, S. Piero a Grado (Pisa), Italy
| | - Cesare Errico
- Laboratory of Bioactive Polymeric Materials for Biomedical and Environmental Applications - UdR INSTM - Department of Chemistry & Industrial Chemistry, University of Pisa, Via Vecchia Livornese,1291, 56010, S. Piero a Grado (Pisa), Italy
| | - Emo Chiellini
- Laboratory of Bioactive Polymeric Materials for Biomedical and Environmental Applications - UdR INSTM - Department of Chemistry & Industrial Chemistry, University of Pisa, Via Vecchia Livornese,1291, 56010, S. Piero a Grado (Pisa), Italy
| |
Collapse
|
27
|
Abstract
Nanotechnology offers many opportunities for enhanced diagnostic and therapeutic medicine against cancer and other diseases. In this review, the special properties that result from the nanoscale size of quantum dots, metal colloids, superparamagnetic iron oxide, and carbon-based nanostructures are reviewed and interpreted against a background of the structural and electronic detail that gives rise to their nanotechnologic behavior. The detection and treatment of cancer is emphasized, with special attention paid to the biologic targeting of the disease. The future of nanotechnology in cancer research and clinical practice is projected to focus on 'theranostic' nanoparticles that are both diagnostic and therapeutic by design.
Collapse
|
28
|
Davaran S, Omidi Y, Mohammad Reza Rashidi, Anzabi M, Shayanfar A, Ghyasvand S, Vesal N, Davaran F. Preparation and in vitro Evaluation of Linear and Star-branched PLGA Nanoparticles for Insulin Delivery. J BIOACT COMPAT POL 2008. [DOI: 10.1177/0883911507088276] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Biodegradable nanoparticles, as drug delivery paradigms, have been extensively used for delivery of a wide range of small molecules as well as macromolecules, such as peptides, proteins, and genes. The morphological modification may improve the physicochemical characteristics of the biodegradable polymers. In the current investigation, the synthesis and characterization of linear, poly(D,L-lactide-co-glycolide) (PLGA)-poly(ethylene glycol) (PEG-PLGA), star-branched β-cyclodextrin-PLGA (β-CD-PLGA), and glucose-PLGA (Glu-PLGA) copolymers containing insulin as a model peptide drug have been reported. Linear and star-branched copolymers of PLGA were synthesized by bulk melt polymerization of the lactones (lactide and glycolide) in the presence of PEG, glucose, or β-CD using Sn-octoate as catalyst. Nanoparticles were prepared by a modified (w1/o/w 2) double emulsion method. Bovine insulin was successfully encapsulated into the linear and star-branched PLGA nanoparticles with retention of insulin stability and the nanoparticles preparation process was optimized to reduce the burst effect and provide in vitro sustained release. The average particle size of samples was 120—355 nm. The cumulative amount of 65—84% insulin was released from the samples after 24 days. The yield of encapsulation of insulin was superior to 95%. Based on these findings, it is suggested that the novel PLGA nanoparticles can be used as a carrier for prolonged delivery of protein—peptide drugs.
Collapse
Affiliation(s)
- Soodabeh Davaran
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran, , Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Yadollah Omidi
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | - Maryam Anzabi
- Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ali Shayanfar
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sohrab Ghyasvand
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Nezamaldin Vesal
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Farzaneh Davaran
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran,
| |
Collapse
|
29
|
Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2007; 5:45-68. [DOI: 10.1517/17425247.5.1.45] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
30
|
Devalapally H, Chakilam A, Amiji MM. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007; 96:2547-65. [PMID: 17688284 DOI: 10.1002/jps.20875] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
A number of new molecular entities (NMEs) selected for full-scale development based on their safety and pharmacological data suffer from undesirable physicochemical and biopharmaceutical properties, which lead to poor pharmacokinetics and distribution after in vivo administration. An optimization of the preformulation studies to develop a dosage form with proper drug delivery system to achieve desirable pharmacokinetic and toxicological properties can aid in the accelerated development of these NMEs into therapies. Nanoparticulate drug delivery systems show a promising approach to obtain desirable druglike properties by altering the biopharmaceutics and pharmacokinetics properties of the molecule. Apart from the advantages of enhancing potential for systemic administration, nanoparticulate drug delivery systems can also be used for site-specific delivery, thus alleviating unwanted toxicity due to nonspecific distribution, improve patient compliance, and provide favorable clinical outcomes. This review summarizes some of the parameters and approaches that can be used to evaluate nanoparticulate drug delivery systems in early stages of formulation development.
Collapse
Affiliation(s)
- Harikrishna Devalapally
- Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 110 Mugar Life Sciences Building, Boston, Massachusetts 02115, USA
| | | | | |
Collapse
|
31
|
Yang YY, Wang Y, Powell R, Chan P. Reduced sinoatrial cAMP content plays a role in postnatal heart rate slowing in the rabbit. Clin Exp Pharmacol Physiol 2007; 33:557-62. [PMID: 16700894 DOI: 10.1111/j.1440-1681.2006.04408.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
1. Decreasing heart rate during development is known to be the result of parasympathetic nervous system maturation that depresses the pacemaker current (If) by acetylcholine (ACh). However, a direct effect of ACh on If has been ruled out and the involvement of other secondary messengers, such as cAMP, was verified in previous studies. Therefore, we hypothesized that reduced basal cAMP production in sinoatrial (SA) nodal cells may contribute to the slowing of heart rate after birth. 2. The electrocardiogram and heart rate variability (HRV) were documented and measured in vivo and in vitro (in isolated perfused Langendorff preparations) for rabbits aged 2, 4, 6, 8 and 12 weeks. Sinoatrial node action potential (AP) recording and perforated patch-clamp analyses were used to investigate the spontaneous depolarization rate and pacemaker If currents. Concentrations of cAMP in SA nodal tissues were determined by radioimmunoassay. Relative expression of adenylate cyclases (ADCY1, 5) and phosphodiesterases (PDE1A, 4A and 8A) were quantified by real-time reverse transcription-polymerase chain reaction. 3. Significantly reduced heart rate, but unchanged HRV, was observed in perfused hearts in the older age groups, accompanied with a slowed phase 4 spontaneous depolarization rate (90.5 +/- 4.7 vs 49.6 +/- 2.6 mV/s for 2 week vs 4 week hearts, respectively; n = 5; P < 0.05), a negative shift of the If threshold potential (-45.5 +/- 3.0 vs -51.1 +/- 6.0 mV for 2 week vs 4 week hearts, respectively; n = 9; P < 0.05) and decreasing basal levels of SA nodal cAMP (0.31 +/- 0.05 vs 0.025 +/- 0.002 micromol/L for 2 week vs 4 week hearts, respectively; n = 6; P < 0.05). Gene expression levels of PDE1A, 4A and 8A were increased in the 12 week group compared with the 2 week group 1.5-, 2- and 1.8-fold, respectively (P < 0.05), with little change in ADCY1 and 5. 4. These data suggest that, in addition to autonomic innervation, slowing of heart rate during postnatal maturation can be attributed to a negative shift of the If activation caused by diminished baseline cAMP content in SA nodal cells.
Collapse
Affiliation(s)
- Yi-Yan Yang
- Institute of Bioengineering and Nanotechnology, Singapore.
| | | | | | | |
Collapse
|
32
|
Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 2007; 120:11-7. [PMID: 17509718 DOI: 10.1016/j.jconrel.2007.04.004] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2006] [Revised: 03/14/2007] [Accepted: 04/09/2007] [Indexed: 11/22/2022]
Abstract
The morphologies of poly(lactic acid)-b-Pluronic-b-poly(lactic acid) (PLA-F127-PLA) aggregates in aqueous solutions were reported previously to be vesicular nano-particles by our group. In the present study, we seek to investigate the feasibility of using PLA-F127-PLA vesicles as oral delivery carrier for insulin. Both in vitro and in vivo release behavior of insulin loaded in PLA-F127-PLA vesicles were studied. A biphasic release behavior was observed for the in vitro release of insulin from PLAF127-29 vesicles. More importantly, it was found in the diabetic mice tests that the blood glucose concentration of oral insulin-loaded PLAF127-29 vesicles decreased from 18.5 to 5.3 mmol/L within 4.5 h and the minimum blood glucose concentration (about 4.5 mmol/L) was achieved after about 5 h. Furthermore, the blood glucose concentration was maintained at this level for at least an additional 18.5 h. These results proved that PLA-F127-PLA vesicles could be promising polymeric carriers for oral insulin delivery application due to their prolonged hypoglycemic effect.
Collapse
|
33
|
Reis CP, Ribeiro AJ, Neufeld RJ, Veiga F. Alginate microparticles as novel carrier for oral insulin delivery. Biotechnol Bioeng 2007; 96:977-89. [PMID: 17001630 DOI: 10.1002/bit.21164] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Alginate microparticles produced by emulsification/internal gelation were investigated as a promising carrier for insulin delivery. The procedure involves the dispersion of alginate solution containing insulin protein, into a water immiscible phase. Gelation is triggered in situ by instantaneous release of ionic calcium from carbonate complex via gentle pH adjustment. Particle size is controlled through the emulsification parameters, yielding insulin-loaded microparticles. Particle recovery was compared using several washing protocols. Recovery strategies are proposed and the influence on particle mean size, morphology, recovery yield (RY), encapsulation efficiency, insulin release profile, and structural integrity of released insulin were evaluated. Spherical micron-sized particles loaded with insulin were produced. The recovery process was optimized, improving yield, and ensuring removal of residual oil from the particle surface. The optimum recovery strategy consisted in successive washing with a mixture of acetone/hexane/isopropanol coupled with centrifugation. This strategy led to small spherical particles with an encapsulation efficiency of 80% and a RY around 70%. In vitro release studies showed that alginate itself was not able to suppress insulin release in acidic media; however, this strategy preserves the secondary structure of insulin. Particles had a mean size lower than the critical diameter necessary to be orally absorbed through the intestinal mucosa followed by their passage to systemic circulation and thus can be considered as a promising technology for insulin delivery.
Collapse
Affiliation(s)
- Catarina Pinto Reis
- Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
| | | | | | | |
Collapse
|
34
|
Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23:1417-50. [PMID: 16779701 DOI: 10.1007/s11095-006-0284-8] [Citation(s) in RCA: 511] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2005] [Accepted: 03/01/2006] [Indexed: 01/19/2023]
Abstract
The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the "magic bullet" proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.
Collapse
Affiliation(s)
- Patrick Couvreur
- Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Université de Paris Sud, 5 Rue J.B. Clément, 92 296, Chatenay-Malabry Cedex, France
| | | |
Collapse
|